DermTech Inc. has agreed to pay up to $5 million to resolve allegations that it submitted false claims to Medicare related to its skin cancer tests, which were found to be unreliable. The Office of Public Affairs announced that the resolution addresses concerns over the accuracy and validity of the company’s testing procedures. The settlement aims to ensure accountability and foster trust in medical testing. The allegations highlighted issues with the claims that DermTech’s tests could reliably detect skin cancer, leading to improper Medicare billing practices. By addressing these concerns, DermTech seeks to reaffirm its commitment to integrity in its operations and to the healthcare community. This action underscores the importance of compliance in medical billing and the rigorous standards expected in healthcare services to protect patients and ensure the reliability of diagnostic tests.
For more details and the full reference, visit the source link below: